Amicus Therapeutics, Inc. (NASDAQ:FOLD) Expected to Announce Earnings of -$0.23 Per Share

Analysts expect Amicus Therapeutics, Inc. (NASDAQ:FOLDGet Rating) to post earnings of ($0.23) per share for the current fiscal quarter, Zacks reports. Three analysts have issued estimates for Amicus Therapeutics’ earnings, with the highest EPS estimate coming in at ($0.19) and the lowest estimate coming in at ($0.27). Amicus Therapeutics posted earnings of ($0.19) per share during the same quarter last year, which suggests a negative year-over-year growth rate of 21.1%. The business is expected to report its next quarterly earnings report on Monday, January 1st.

According to Zacks, analysts expect that Amicus Therapeutics will report full year earnings of ($0.89) per share for the current fiscal year, with EPS estimates ranging from ($0.97) to ($0.76). For the next financial year, analysts forecast that the company will report earnings of ($0.12) per share, with EPS estimates ranging from ($0.36) to $0.03. Zacks Investment Research’s earnings per share calculations are an average based on a survey of research firms that follow Amicus Therapeutics.

Amicus Therapeutics (NASDAQ:FOLDGet Rating) last posted its earnings results on Monday, May 9th. The biopharmaceutical company reported ($0.30) EPS for the quarter, missing the consensus estimate of ($0.24) by ($0.06). Amicus Therapeutics had a negative return on equity of 95.05% and a negative net margin of 84.97%. The business had revenue of $78.72 million for the quarter, compared to analyst estimates of $76.97 million. During the same quarter in the prior year, the business earned ($0.25) earnings per share.

Several research firms recently commented on FOLD. SVB Leerink cut their target price on shares of Amicus Therapeutics from $16.00 to $14.00 and set an “outperform” rating on the stock in a research report on Thursday, February 24th. The Goldman Sachs Group began coverage on shares of Amicus Therapeutics in a research report on Wednesday, April 13th. They set a “neutral” rating on the stock. Finally, StockNews.com began coverage on shares of Amicus Therapeutics in a research report on Thursday, March 31st. They set a “hold” rating on the stock. Five investment analysts have rated the stock with a hold rating and five have issued a buy rating to the company. According to data from MarketBeat.com, the company currently has an average rating of “Buy” and an average price target of $15.00.

NASDAQ:FOLD traded down $0.35 during mid-day trading on Tuesday, hitting $7.59. 2,023,098 shares of the company’s stock were exchanged, compared to its average volume of 3,478,714. The company has a 50 day simple moving average of $8.23 and a 200-day simple moving average of $9.49. The company has a current ratio of 4.00, a quick ratio of 3.81 and a debt-to-equity ratio of 1.63. Amicus Therapeutics has a fifty-two week low of $5.91 and a fifty-two week high of $12.63. The firm has a market capitalization of $2.13 billion, a P/E ratio of -7.82 and a beta of 1.42.

In other news, COO Bradley L. Campbell sold 10,940 shares of Amicus Therapeutics stock in a transaction on Friday, March 18th. The shares were sold at an average price of $10.00, for a total value of $109,400.00. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, Director Margaret G. Mcglynn sold 15,000 shares of the business’s stock in a transaction on Monday, May 2nd. The shares were sold at an average price of $6.99, for a total transaction of $104,850.00. Following the sale, the director now owns 38,034 shares of the company’s stock, valued at approximately $265,857.66. The disclosure for this sale can be found here. Insiders sold a total of 39,172 shares of company stock valued at $331,874 in the last quarter. 2.50% of the stock is currently owned by company insiders.

A number of hedge funds have recently made changes to their positions in FOLD. First Horizon Advisors Inc. increased its stake in Amicus Therapeutics by 155.7% during the 4th quarter. First Horizon Advisors Inc. now owns 2,917 shares of the biopharmaceutical company’s stock valued at $32,000 after purchasing an additional 1,776 shares in the last quarter. Parallel Advisors LLC boosted its holdings in Amicus Therapeutics by 1,173.1% during the 4th quarter. Parallel Advisors LLC now owns 3,361 shares of the biopharmaceutical company’s stock worth $39,000 after acquiring an additional 3,097 shares during the last quarter. Dark Forest Capital Management LP boosted its holdings in Amicus Therapeutics by 1,967.5% during the 3rd quarter. Dark Forest Capital Management LP now owns 4,838 shares of the biopharmaceutical company’s stock worth $46,000 after acquiring an additional 4,604 shares during the last quarter. Copernicus Capital Management LLC purchased a new position in Amicus Therapeutics during the 3rd quarter worth $96,000. Finally, Running Point Capital Advisors LLC purchased a new position in Amicus Therapeutics during the 1st quarter worth $99,000.

About Amicus Therapeutics (Get Rating)

Amicus Therapeutics, Inc, a biotechnology company, focuses on discovering, developing, and delivering medicines for rare diseases. Its commercial product and product candidates include Galafold, an oral precision medicine for the treatment of adults with a confirmed diagnosis of Fabry disease and an amenable galactosidase alpha gene variant based on in vitro assay data.

Read More

Get a free copy of the Zacks research report on Amicus Therapeutics (FOLD)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Amicus Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amicus Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.